Pharma Two B

Company Overview

Snapshot

Founded in March 2007 by Dr. Nurit Livnah, Pharma Two B operates with 1–10 employees. The company has raised $46.11 million across 4 funding rounds from 8 investors. In September 2024, Pharma Two B and Hepion Pharmaceuticals, Inc. announced the filing of a Registration Statement on Form F-4 related to a proposed merger.

Business overview

Pharma Two B is a clinical-stage pharmaceutical company focused on developing differentiated and value-added products by combining previously approved drugs. The company aims to enhance efficacy, safety, and delivery profiles to increase clinical value and accelerate regulatory approval timelines. Its lead product candidate, P2B001, is being investigated as a treatment for early-stage Parkinson's disease, having shown positive results in Phase II clinical trials and currently undergoing Phase III trials. Pharma Two B operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the healthcare and life sciences markets.

Strategic signal

A significant strategic shift for Pharma Two B was signaled in September 2024 with the announcement of a proposed merger with Hepion Pharmaceuticals, Inc. and the filing of a Registration Statement on Form F-4. This move indicates a potential pathway for the Israeli biotech to go public, as reported in July 2024, before seeking FDA approval for its lead product. This development suggests a strategic maneuver to secure public market access and potentially accelerate the commercialization of its drug candidates, particularly P2B001 for Parkinson's disease, offering a new trajectory for the company amidst its clinical development efforts.

Company Intelligence Q&A

What was the most recent significant corporate development for Pharma Two B?

In September 2024, Pharma Two B and Hepion Pharmaceuticals, Inc. announced the filing of a Registration Statement on Form F-4 related to a proposed merger, indicating a potential path to public markets.

What is Pharma Two B's lead product candidate and its current development stage?

Pharma Two B's lead product candidate is P2B001, which is being developed as a treatment for early-stage Parkinson's disease and is currently undergoing Phase III clinical trials.

When did Pharma Two B announce positive topline results from its pivotal Phase III study for P2B001?

In December 2021, Pharma Two B announced positive topline results from its pivotal Phase III study of P2B001 for early Parkinson's disease.

Did Pharma Two B secure any licensing agreements for P2B001?

In November 2021, Pharma Two B announced a licensing and investment agreement with Myung In Pharm (MIP) for P2B001 in South Korea.

What was the outcome of the production of the drug in March 2025?

In March 2025, a failure in drug production led Pharma Two B to request an order for the initiation of proceedings.